I remain of my opinion that nnz-2591 with a perfect planning of...

I remain of my opinion that nnz-2591 with a perfect planning of the endpoints after a TYPE C meeting with the FDA for PMD, followed in the next few months by Pitt Hopkins (same FDA division), with perhaps Angelman advancing to phase 3, with perhaps the resumption of PW with a more streamlined protocol and after having disclosed the series of hidden preclinical trials with patents in order, the whole package will be complete and nnz-2591 will become a small BLOCKBUSTER, perhaps to be used in combination for other pathologies with drugs already approved. Having said all this, I do not see and do not understand why a BP (given the lack of multifunctional drugs and given the exclusivity of the patents in the next few years of established BLOCKBUSTERs) should wait for the end of phase 3 or the possible merger with Acadia and then take everything in a few years paying much more and losing years of development of various pathologies at the same time as opening of possible dozens of trials (something that both Neuren and Acadia are not able to do) and therefore losing any potential turnover in the years to come, then obviously everything depends on how much our BOD intends to have in terms of cash to accept an unmissable full package offer.